Track how companies discuss tariffs and trade policies in their earnings calls, and understand their impact across different industries and regions.
we estimate to be trending towards the lower end of $300 million and $400 million at today's announced tariffs, so almost 1 point of negative EBITDA margin embedded in the guide.
I think they are more comfortable with the fact that there will be tariffs. However, I think they have more certainty now than in the beginning of the year when everyone was confused about exactly what would happen.
30% of our customers are impacted by tariffs. But here's the interesting thing. Of the $56 billion that we have outstanding in C&I, only 3% are significantly impacted in a direct way by tariffs.
In the second quarter, we estimate that the increase in tariff rates negatively impacted our EBITDA by approximately $15 million.
We are seeing impacts in our Forest Products, and metals and our autos business.
Given the uncertain tariff structure, it's difficult to forecast third quarter margins.
We currently expect the recently implemented tariffs globally to increase our 2025 cost of sales by approximately 1% of revenue.
the situation of tariffs and geopolitics disrupting supply chains, I think that's not over.
In theory, tariffs should not have huge impact on the innovation biopharma ecosystem, mostly because of the low cost of goods sold relative to other industries like hardcore manufacturing.
we expect to absorb the impact of tariffs currently in place, primarily in Europe and China.